31 results
SC 14D9
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
in an appraisal proceeding, stating that “proof of value by any techniques or methods which are generally considered acceptable in the financial community
SC TO-T
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Third party tender offer statement
5:24pm
section 584(a) 11 A financial institution 12 A middleman known in the investment community as a nominee or custodian 13 A trust exempt from tax under
8-K
EX-10.1
l8u8vyl3tyf3ez 96p
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
10-Q
qj8ti
17 May 21
Quarterly report
4:26pm
DEF 14A
8i4ep3sg5h6
30 Apr 21
Definitive proxy
9:13am
10-K
mubz rn6bb3
29 Mar 21
Annual report
4:26pm
424B4
d9lxsr nk3ozmcc
3 Dec 20
Prospectus supplement with pricing info
4:48pm
S-1/A
whneeaoxcz7hci
30 Nov 20
IPO registration (amended)
6:05am